name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy and stone extraction of stone(s) over 2 cm, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy of branching stone(s) with antegrade stent placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy of branching stone(s) with antegrade uretroscopy, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy of branching stone(s) with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy of stone(s) over 2 cm with antegrade stent placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy of stone(s) over 2 cm with antegrade uretroscopy, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy of stone(s) over 2 cm with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy of stones in multiple locations with antegrade stent placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy of stones in multiple locations with antegrade uretroscopy, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy of stones in multiple locations with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy of ureter stones with antegrade stent placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy of ureter stones with antegrade uretroscopy, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy of ureter stones with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy with complicated anatomy with antegrade stent placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy with complicated anatomy with antegrade uretroscopy, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy with complicated anatomy with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy, extraction of branching stone(s) with antegrade stent placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy, extraction of branching stone(s) with antegrade uretroscopy, antegrade stent placement, and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy, extraction of stone(s) over 2 cm with antegrade stent placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy, extraction of stones in multiple locations with antegrade stent placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy, extraction of stones in multiple locations with antegrade uretroscopy, antegrade stent placement, and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy, extraction of ureter stones with antegrade stent placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy, extraction of ureter stones with antegrade uretroscopy, antegrade stent placement, and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy, extraction with complicated anatomy with antegrade stent placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy, extraction with complicated anatomy with antegrade uretroscopy, antegrade stent placement, and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stone(s) with lithotripsy, stone extration of stone(s) over 2 cm with antegrade uretroscopy, antegrade stent placement, and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stones in multiple locations with antegrade stent placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of stones in multiple locations with antegrade ureteroscopy, using imaging guidance


name: Complex percutaneous nephrolithotomy of stones in multiple locations with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of ureter stones with antegrade stent placement, using imaging guidance


name: Complex percutaneous nephrolithotomy of ureter stones with antegrade ureteroscopy, using imaging guidance


name: Complex percutaneous nephrolithotomy of ureter stones with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous nephrolithotomy with complicated anatomy with antegrade stent placement, using imaging guidance


name: Complex percutaneous nephrolithotomy with complicated anatomy with antegrade ureteroscopy, using imaging guidance


name: Complex percutaneous nephrolithotomy with complicated anatomy with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous nephrolithotomy with extraction of branching stone(s), using imaging guidance


name: Complex percutaneous nephrolithotomy with extraction of stones in multiple locations, using imaging guidance


name: Complex percutaneous nephrolithotomy with extraction of ureter stones, using imaging guidance


name: Complex percutaneous nephrolithotomy with extraction with complicated anatomy, using imaging guidance


name: Complex percutaneous nephrolithotomy with lithotripsy of branching stone(s) using imaging guidance


name: Complex percutaneous nephrolithotomy with lithotripsy of stone(s) over 2 cm, using imaging guidance


name: Complex percutaneous nephrolithotomy with lithotripsy of stones in multiple locations using imaging guidance


name: Complex percutaneous nephrolithotomy with lithotripsy of ureter stones using imaging guidance


name: Complex percutaneous nephrolithotomy with lithotripsy with complicated anatomy using imaging guidance


name: Complex percutaneous nephrolithotomy with stone extraction of stone(s) over 2 cm i, using imaging guidance


name: Complex percutaneous pyelolithotomy of branching stone(s) with antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of branching stone(s) with antegrade ureteroscopy, using imaging guidance


name: Complex percutaneous pyelolithotomy of branching stone(s) with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) over 2 cm iwith antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) over 2 cm with antegrade ureteroscopy, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) over 2 cm with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of branching stone(s) with antegrade stent placement and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of branching stone(s) with antegrade uretroscopy and antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of branching stone(s) with antegrade uretroscopy and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of branching stone(s) with antegrade uretroscopy, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of branching stone(s) with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of stone(s) over 2 cm i with antegrade stent placement and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of stone(s) over 2 cm i with antegrade uretroscopy and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of stone(s) over 2 cm iwith antegrade uretroscopy and antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of stone(s) over 2 cm with antegrade uretroscopy, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of stone(s) over 2 cm with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of stones in multiple locations with antegrade stent placement and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of stones in multiple locations with antegrade uretroscopy and antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of stones in multiple locations with antegrade uretroscopy and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of stones in multiple locations with antegrade uretroscopy, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of stones in multiple locations with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of ureter stones with antegrade stent placement and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of ureter stones with antegrade uretroscopy and antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of ureter stones with antegrade uretroscopy and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of ureter stones with antegrade uretroscopy, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction of ureter stones with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction with complicated anatomy with antegrade stent placement and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction with complicated anatomy with antegrade uretroscopy and antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction with complicated anatomy with antegrade uretroscopy and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with extraction with complicated anatomy with antegrade uretroscopy, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy and extraction of branching stone(s), using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy and extraction of stones in multiple locations, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy and extraction of ureter stones, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy and extraction with complicated anatomy, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy and stone extraction of stone(s) over 2 cm, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy of branching stone(s) with antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy of branching stone(s) with antegrade uretroscopy, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy of branching stone(s) with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy of stone(s) over 2 cm uretroscopy, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy of stone(s) over 2 cm with antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy of stone(s) over 2 cm with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy of stones in multiple locations with antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy of stones in multiple locations with antegrade uretroscopy, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy of stones in multiple locations with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy of ureter stones with antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy of ureter stones with antegrade uretroscopy, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy of ureter stones with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy with complicated anatomy with antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy with complicated anatomy with antegrade uretroscopy, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy with complicated anatomy with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy, extraction of branching stone(s) with antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy, extraction of branching stone(s) with antegrade uretroscopy, antegrade stent placement, and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy, extraction of stone(s) over 2 cm with antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy, extraction of stones in multiple locations with antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy, extraction of stones in multiple locations with antegrade uretroscopy, antegrade stent placement, and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy, extraction of ureter stones with antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy, extraction of ureter stones with antegrade uretroscopy, antegrade stent placement, and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy, extraction with complicated anatomy with antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy, extraction with complicated anatomy with antegrade uretroscopy, antegrade stent placement, and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stone(s) with lithotripsy, stone extration of stone(s) over 2 cm with antegrade uretroscopy, antegrade stent placement, and nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stones in multiple locations with antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of stones in multiple locations with antegrade ureteroscopy, using imaging guidance


name: Complex percutaneous pyelolithotomy of stones in multiple locations with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of ureter stones with antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy of ureter stones with antegrade ureteroscopy, using imaging guidance


name: Complex percutaneous pyelolithotomy of ureter stones with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy with complicated anatomy with antegrade stent placement, using imaging guidance


name: Complex percutaneous pyelolithotomy with complicated anatomy with antegrade ureteroscopy, using imaging guidance


name: Complex percutaneous pyelolithotomy with complicated anatomy with nephrostomy tube placement, using imaging guidance


name: Complex percutaneous pyelolithotomy with extraction of branching stone(s), using imaging guidance


name: Complex percutaneous pyelolithotomy with extraction of stones in multiple locations, using imaging guidance


name: Complex percutaneous pyelolithotomy with extraction of ureter stones, using imaging guidance


name: Complex percutaneous pyelolithotomy with extraction with complicated anatomy, using imaging guidance


name: Complex percutaneous pyelolithotomy with lithotripsy of branching stone(s), using imaging guidance


name: Complex percutaneous pyelolithotomy with lithotripsy of stone(s) over 2 cm, using imaging guidance


name: Complex percutaneous pyelolithotomy with lithotripsy of stones in multiple locations, using imaging guidance


name: Complex percutaneous pyelolithotomy with lithotripsy of ureter stones, using imaging guidance


name: Complex percutaneous pyelolithotomy with lithotripsy with complicated anatomy, using imaging guidance


name: Complex percutaneous pyelolithotomy with stone extraction of stone(s) over 2 cm, using imaging guidance


name: Laparoscopy, surgical prostatectomy, simple subtotal (including control of postoperative bleeding, vasectomy, meatotomy, urethral calibration and/or dilation, and internal urethrotomy), includes robotic assistance, when performed


name: Simple surgical subtotal removal of prostate using laparoscope


name: Laparoscopic simple subtotal surgical prostatectomy


name: Robot-assisted laparoscopic simple subtotal surgical prostatectomy urethrotomy


name: Injection of anesthetic agent and/or steroid into arm nerve bundle (brachial plexus)


name: Injection of anesthetic agent and steroid into brachial plexus using imaging guidance


name: Injection of anesthetic agent into brachial plexus using imaging guidance


name: Injection of steroid into brachial plexus using imaging guidance


name: Continuous infusion of anesthetic agent and/or steroid into arm nerve bundle through catheter


name: Continuous infusion of anesthetic agent and steroid into brachial plexus with insertion of catheter using imaging guidance


name: Continuous infusion of anesthetic agent into brachial plexus with insertion of catheter using imaging guidance


name: Continuous infusion of steroid into brachial plexus with insertion of catheter using imaging guidance


name: Injection of anesthetic agent and steroid into axillary nerve using imaging guidance


name: Injection of anesthetic agent into axillary nerve using imaging guidance


name: Injection of steroid into axillary nerve using imaging guidance


name: Injection of anesthetic agent and steroid into sciatic nerve using imaging guidance


name: Injection of anesthetic agent into sciatic nerve using imaging guidance


name: Injection of steroid into sciatic nerve using imaging guidance


name: Continuous infusion of anesthetic agent and/or steroid into lower back and leg nerve (sciatic nerve) through catheter


name: Continuous infusion of anesthetic agent into sciatic nerve with insertion of catheter using imaging guidance


name: Continuous infusion of steroid into sciatic nerve with insertion of catheter using imaging guidance


name: Injection of anesthetic agent and/or steroid into thigh nerve (femoral nerve)


name: Injection of anesthetic agent and steroid into femoral nerve using imaging guidance


name: Injection of anesthetic agent into femoral nerve using imaging guidance


name: Injection of steroid into femoral nerve using imaging guidance


name: Continuous infusion of anesthetic agent and/or steroid into thigh nerve (femoral nerve) through catheter


name: Continuous infusion of anesthetic agent and steroid into femoral nerve with insertion of catheter using imaging guidance


name: Continuous infusion of anesthetic agent into femoral nerve with insertion of catheter using imaging guidance


name: Continuous infusion of steroid into femoral nerve with insertion of catheter using imaging guidance


name: Transluminal dilation of aqueous outflow canal (eg, canaloplasty)


name: Dilation of fluid outflow drainage within eye


name: Dilation of fluid outflow drainage within eye with insertion of device to maintain open channel


name: Implantation of cochlear stimulating system into mastoid bone of skull with magnetic attachment to external speech processor


name: Implantation of osseointegrated implant in skull with removal of less than 100 sq mm surface area of bone deep to outer cranial cortex, with magnetic transcutaneous attachment to external speech processor


name: Implantation of osseointegrated implant in skull within mastoid with magnetic transcutaneous attachment to external speech processor


name: Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside of the mastoid and resulting in removal of greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex


name: Implantation of cochlear stimulating system outside mastoid bone of skull with magnetic attachment to external speech processor


name: Replacement (including removal of existing device), osseointegrated implant, skull


name: Replacement of cochlear stimulating system into mastoid bone of skull with magnetic attachment to external speech processor


name: Removal and replacement of osseointegrated implant in skull involving bony defect less than 100 sq mm surface area of bone deep to outer cranial cortex with magnetic transcutaneous attachment to external speech processor


name: Removal and replacement of osseointegrated implant in skull within mastoid with magnetic transcutaneous attachment to external speech processor


name: Replacement (including removal of existing device), osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside the mastoid and involving a bony defect greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex


name: Replacement of cochlear stimulating system outside mastoid bone of skull with magnetic attachment to external speech processor


name: Removal of entire cochlear stimulating system from skull with attachment through skin to external speech processor


name: Removal of entire cochlear stimulating system from mastoid bone of skull with magnetic attachment to external speech processor


name: Removal of entire osseointegrated implant in skull involving bony defect in less than 100 sq mm surface area of bone deep to outer cranial cortex with magnetic transcutaneous attachment to external speech processor


name: Removal of entire osseointegrated implant in skull within mastoid with magnetic transcutaneous attachment to external speech processor


name: Removal, entire osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside the mastoid and involving a bony defect greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex


name: Limited ultrasound scan of joint or other extremity structure except blood vessels


name: Limited real time ultrasound of muscle of extremity, with image documentation


name: Limited real time ultrasound of muscles of extremity, with image documentation


name: Limited real time ultrasound of nerve of extremity, with image documentation


name: Limited real time ultrasound of nerves of extremity, with image documentation


name: Ultrasound, nerve(s) and accompanying structures throughout their entire anatomic course in one extremity, comprehensive, including real-time cine imaging with image documentation, per extremity


name: Comprehensive ultrasound scan of entire length of nerves in extremity


name: Comprehensive ultrasound of nerves and accompanying structures throughout their entire anatomic course in one extremity with real-time cine imaging with image documentation,


name: Nuclear medicine study, SPECT imaging, 1 area or single acquisition, single day imaging


name: Single photon emission computed tomography (SPECT) imaging of distribution of radiopharmaceutical agents, single acquisition, single day


name: Single photon emission computed tomography (SPECT) imaging of distribution of radiopharmaceutical agents, single acquisition, with vascular flow and blood pool imaging, single day


name: Single photon emission computed tomography (SPECT) radiopharmaceutical localization of inflammation, single acquisition, single day


name: Single photon emission computed tomography (SPECT) radiopharmaceutical localization of inflammation, single acquisition, with vascular flow and blood pool imaging, single day


name: Single photon emission computed tomography (SPECT) radiopharmaceutical localization of tumor, single acquisition, single day


name: Single photon emission computed tomography (SPECT) radiopharmaceutical localization of tumor, single acquisition, with vascular flow and blood pool imaging, single day


name: Nuclear medicine study, SPECT imaging with concurrent CT scan, 1 area or single acquisition, single day imaging


name: Single photon emission computed tomography (SPECT) imaging of distribution of radiopharmaceutical agent, single acquisition, with concurrently acquired computed tomography (CT) transmission, single day


name: Single photon emission computed tomography (SPECT) radiopharmaceutical localization of inflammation, single acquisition, with concurrently acquired computed tomography (CT) transmission, single day


name: Single photon emission computed tomography (SPECT) radiopharmaceutical localization of tumor in pelvis, with vascular flow and blood pool imaging, with concurrently acquired computed tomography (CT) transmission, single day


name: Single photon emission computed tomography (SPECT) radiopharmaceutical localization of tumor, single acquisition, with concurrently acquired computed tomography (CT) transmission, single day


name: Nuclear medicine study, SPECT imaging, at least 2 areas or separate acquisitions, single day imaging, or single area or acquisition over multiple days


name: Single photon emission computed tomography (SPECT) imaging of distribution of radiopharmaceutical agent in chest and abdomen, single day


name: Single photon emission computed tomography (SPECT) imaging of distribution of radiopharmaceutical agent in chest and abdomen, with vascular flow and blood pool imaging, single day


name: Single photon emission computed tomography (SPECT) imaging of distribution of radiopharmaceutical agent with vascular flow and blood pool imaging, single acquisition over multiple days


name: Single photon emission computed tomography (SPECT) imaging of distribution of radiopharmaceutical agent, single acquisition over multiple days


name: Single photon emission computed tomography (SPECT) imaging of distribution of radiopharmaceutical agents in chest and abdomen, single day


name: Single photon emission computed tomography (SPECT) imaging of distribution of radiopharmaceutical agents in chest and abdomen, with vascular flow and blood pool imaging, single day


name: Single photon emission computed tomography (SPECT) imaging of distribution of radiopharmaceutical agents with vascular flow and blood pool imaging, single acquisition over multiple days


name: Single photon emission computed tomography (SPECT) imaging of distribution of radiopharmaceutical agents, single acquisition over multiple days


name: Single photon emission computed tomography (SPECT) radiopharmaceutical localization of inflammation in chest and abdomen, single day


name: Single photon emission computed tomography (SPECT) radiopharmaceutical localization of inflammation in chest and abdomen, with vascular flow and blood pool imaging, single day


name: Single photon emission computed tomography (SPECT) radiopharmaceutical localization of inflammation, single acquisition over multiple days


name: Single photon emission computed tomography (SPECT) radiopharmaceutical localization of inflammation, with vascular flow and blood pool imaging, single acquisition over multiple days


name: Single photon emission computed tomography (SPECT) radiopharmaceutical localization of tumor in chest and abdomen, single day


name: Single photon emission computed tomography (SPECT) radiopharmaceutical localization of tumor in chest and abdomen, with vascular flow and blood pool imaging, single day


name: Single photon emission computed tomography (SPECT) radiopharmaceutical localization of tumor with vascular flow and blood pool imaging, single acquisition over multiple days


name: Single photon emission computed tomography (SPECT) radiopharmaceutical localization of tumor, single acquisition over multiple days


name: Nuclear medicine study, SPECT imaging with concurrent CT scan, at least 2 areas or separate acquisitions, single day imaging, or single area or acquisition over multiple days


name: Single photon emission computed tomography (SPECT) imaging of distribution of radiopharmaceutical agent in chest and abdomen with concurrently acquired computed tomography (CT) transmission, single day


name: Single photon emission computed tomography (SPECT) imaging of distribution of radiopharmaceutical agent in chest and abdomen, with vascular flow and blood pool imaging, with concurrently acquired computed tomography (CT) transmission, single day


name: Single photon emission computed tomography (SPECT) imaging of distribution of radiopharmaceutical agents in chest and abdomen with concurrently acquired computed tomography (CT) transmission, single day


name: Single photon emission computed tomography (SPECT) imaging of distribution of radiopharmaceutical agents in chest and abdomen, with vascular flow and blood pool imaging, with concurrently acquired computed tomography (CT) transmission, single day


name: Single photon emission computed tomography (SPECT) radiopharmaceutical localization of tumor in chest and abdomen with concurrently acquired computed tomography (CT) transmission, single day


name: Single photon emission computed tomography (SPECT) radiopharmaceutical localization of tumor in chest and abdomen, with vascular flow and blood pool imaging, with concurrently acquired computed tomography (CT) transmission, single day


name: Drug metabolism (eg, pharmacogenomics) genomic sequence analysis panel, must include testing of at least 6 genes, including CYP2C19, CYP2D6, and CYP2D6 duplication/deletion analysis


name: Inherited bone marrow failure syndromes (IBMFS) (eg, Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, GATA2 deficiency syndrome, congenital amegakaryocytic thrombocytopenia) sequence analysis panel, must include sequencing of at least 30 genes, including BRCA2, BRIP1, DKC1, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, GATA1, GATA2, MPL, NHP2, NOP10, PALB2, RAD51C, RPL11, RPL35A, RPL5, RPS10, RPS19, RPS24, RPS26, RPS7, SBDS, TERT, and TINF2


name: Gene sequence analysis panel at least 30 genes associated with inherited bone marrow failure syndromes


name: Genetic sequence analysis panel for inherited bone marrow failure syndromes (IBMFS) with sequencing of at least 30 genes


name: Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; RNA analysis


name: Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis


name: Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis


name: Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; hepatitis B surface antigen (HBsAg), quantitative


name: Infectious agent detection by nucleic acid (DNA or RNA); Anaplasma phagocytophilum, amplified probe technique


name: Infectious agent detection by nucleic acid (DNA or RNA); Babesia microti, amplified probe technique


name: Detection of Babesia microtim by amplified nucleic acid probe technique


name: Detection of Babesia microti nucleic acid by amplified DNA probe technique


name: Detection of Babesia microti nucleic acid by amplified RNA probe technique


name: Infectious agent detection by nucleic acid (DNA or RNA); Borrelia miyamotoi, amplified probe technique


name: Infectious agent detection by nucleic acid (DNA or RNA); Ehrlichia chaffeensis, amplified probe technique


name: Detection of Ehrlichia chaffeensis nucleic acid by amplified RNA probe technique


name: Infectious agent detection by nucleic acid (DNA or RNA); Orthopoxvirus (eg, monkeypox virus, cowpox virus, vaccinia virus), amplified probe technique, each


name: Detection of cowpox virus nucleic acid by amplified DNA probe technique


name: Detection of cowpox virus nucleic acid by amplified RNA probe technique


name: Detection of monkeypox virus nucleic acid by amplified DNA probe technique


name: Detection of monkeypox virus nucleic acid by amplified RNA probe technique


name: Detection of Orthopox virus nucleic acid by amplified RNA probe technique


name: Detection of vaccinia virus nucleic acid by amplified DNA probe technique


name: Detection of vaccinia virus nucleic acid by amplified RNA probe technique


name: Infectious agent genotype analysis by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), mutation identification in targeted region(s)


name: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), mutation identification in targeted region by DNA genotype analysis


name: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), mutation identification in targeted region by RNA genotype analysis


name: Evaluation of gastric emptying by measurement of radiolabeled carbon dioxide in breath specimens


name: Genomic sequence analysis of 42 genes for detection of abnormalities associated with inherited thrombocytopenia (low platelet count)


name: Genomic sequence analysis of 42 genes associated with inherited thrombocytopenia in amniotic fluid specimen


name: Genomic sequence analysis of 42 genes associated with inherited thrombocytopenia in blood specimen


name: Genomic sequence analysis of 42 genes associated with inherited thrombocytopenia in buccal swab specimen


name: Oncology, response to radiation, cell-free DNA, quantitative branched chain DNA amplification, plasma, reported as a radiation toxicity score


name: Evaluation of response to radiation in cell-free DNA by quantitative branched chain DNA amplification, reported as radiation toxicity score


name: CEP72 (centrosomal protein, 72-KDa), NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (eg, drug metabolism) gene analysis, common variants


name: Oncology (thyroid), DNA and mRNA, next-generation sequencing analysis of 112 genes, fine needle aspirate or formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic prediction of cancer recurrence, reported as a categorical risk result (low, intermediate, high)


name: Next-generation DNA and RNA sequencing of 112 genes in tumor specimen, with algorithmic prediction of cancer recurrence, reported as a categorical risk result (low, intermediate, high)


name: DNA and mRNA next-generation sequencing analysis of 112 genes in fine needle aspirate of thyroid tissue, algorithmic prediction of thyroid cancer recurrence, reported as categorical risk result (low, intermediate, high)


name: DNA and mRNA next-generation sequencing analysis of 112 genes in formalin-fixed paraffin-embedded (FFPE) thyroid tissue with algorithmic prediction of thyroid cancer recurrence, reported as categorical risk result (low, intermediate, high)


name: Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score


name: PCR measurement of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), in tumor tissue, with algorithmic interpretation reported as a recurrence risk score


name: Neurology (Alzheimer disease), mRNA, gene expression profiling by RNA sequencing of 24 genes, whole blood, algorithm reported as predictive risk score


name: Pain management, mRNA, gene expression profiling by RNA sequencing of 36 genes, whole blood, algorithm reported as predictive risk score


name: Psychiatry (mood disorders), mRNA, gene expression profiling by RNA sequencing of 144 genes, whole blood, algorithm reported as predictive risk score


name: Psychiatry (stress disorders), mRNA, gene expression profiling by RNA sequencing of 72 genes, whole blood, algorithm reported as predictive risk score


name: Psychiatry (suicidal ideation), mRNA, gene expression profiling by RNA sequencing of 54 genes, whole blood, algorithm reported as predictive risk score


name: Longevity and mortality risk, mRNA, gene expression profiling by RNA sequencing of 18 genes, whole blood, algorithm reported as predictive risk score


name: mRNA gene expression profiling of 18 genes in whole blood for detection of abnormalities associated with life expectancy, algorithm reported as predictive risk score


name: Oncology (breast ductal carcinoma in situ), protein expression profiling by immunohistochemistry of 7 proteins (COX2, FOXA1, HER2, Ki-67, p16, PR, SIAH2), with 4 clinicopathologic factors (size, age, margin status, palpability), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a recurrence risk score


name: Protein expression profiling by immunohistochemistry of 7 proteins (COX2, FOXA1, HER2, Ki-67, p16, PR, SIAH2), with 4 clinicopathologic factors (size, age, margin status, palpability), in breast ductal carcinoma in situ tumor tissue, algorithm reported as recurrence risk score


name: Oncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing of at least 20 molecular features (eg, human and/or microbial mRNA), saliva, algorithm reported as positive or negative for signature associated with malignancy


name: mRNA gene expression profiling of at least 20 molecular features in saliva, algorithm reported as positive or negative for signature associated with mouth or mouth and pharynx cancer


name: Oncology (pan tumor), whole genome sequencing of paired malignant and normal DNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and variant identification


name: Whole genome sequencing of paired tumor and normal DNA specimens, in tissue, blood or bone marrow, with comparative sequence analyses and variant identification


name: Whole genome sequencing of paired malignant and normal DNA specimens in blood specimen with comparative sequence analyses and variant identification


name: Whole genome sequencing of paired malignant and normal DNA specimens in bone marrow specimen with comparative sequence analyses and variant identification


name: Whole genome sequencing of paired malignant and normal DNA specimens in formalin-fixed paraffin-embedded (FFPE) tissue specimen with comparative sequence analyses and variant identification


name: Whole genome sequencing of paired malignant and normal DNA specimens in fresh tissue specimen with comparative sequence analyses and variant identification


name: Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification


name: Whole transcriptome sequencing of paired tumor and normal DNA specimens, in tissue, blood or bone marrow, with comparative sequence analyses and expression level and chimeric transcript identification


name: Whole transcriptome sequencing of paired malignant and normal RNA specimens in blood specimen with comparative sequence analyses and expression level and chimeric transcript identification


name: Whole transcriptome sequencing of paired malignant and normal RNA specimens in bone marrow specimen with comparative sequence analyses and expression level and chimeric transcript identification


name: Whole transcriptome sequencing of paired malignant and normal RNA specimens in formalin-fixed paraffin-embedded (FFPE) specimen with comparative sequence analyses and expression level and chimeric transcript identification


name: Whole transcriptome sequencing of paired malignant and normal RNA specimens in fresh tissue specimen with comparative sequence analyses and expression level and chimeric transcript identification


name: Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal DNA specimens, fresh frozen tissue, blood, or bone marrow, comparative structural variant identification


name: Whole transcriptome sequencing of paired tumor and normal DNA specimens, in tissue, blood or bone marrow, with comparative structural variant identification


name: Whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens in blood specimen with comparative structural variant identification


name: Whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens in bone marrow specimen with comparative structural variant identification


name: Whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens in fresh tissue specimen with comparative structural variant identification


name: Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens, fresh tissue, blood, or bone marrow, comparative sequence analyses and variant identification


name: Whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens in blood specimen with comparative sequence analyses and variant identification


name: Whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens in bone marrow specimen with comparative sequence analyses and variant identification


name: Whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens in fresh tissue specimen with comparative sequence analyses and variant identification


name: Infectious agent detection by nucleic acid (DNA or RNA), Bartonella henselae and Bartonella quintana, droplet digital PCR (ddPCR);


name: Detection of Bartonella henselae and Bartonella quintana DNA by droplet digital polymerase chain reaction (ddPCR)


name: Infectious agent detection by nucleic acid (DNA or RNA), Bartonella henselae and Bartonella quintana, droplet digital PCR (ddPCR); following liquid enrichment


name: Detection of Bartonella henselae and Bartonella quintana DNA by droplet digital polymerase chain reaction (ddPCR) following liquid enrichment


name: Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index


name: Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; hypoxic


name: Functional assessment of red blood cell (RBC) adhesion to endothelial adhesion molecules in hypoxic whole blood specimen, with algorithmic analysis and result reported as RBC adhesion index


name: Functional assessment of red blood cell (RBC) adhesion to subendothelial adhesion molecules in hypoxic whole blood specimen, with algorithmic analysis and result reported as RBC adhesion index


name: Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; normoxic


name: Functional assessment of red blood cell (RBC) adhesion to endothelial adhesion molecules in normoxic whole blood specimen, with algorithmic analysis and result reported as RBC adhesion index


name: Functional assessment of red blood cell (RBC) adhesion to subendothelial adhesion molecules in normoxic whole blood specimen, with algorithmic analysis and result reported as RBC adhesion index


name: Hematology, red blood cell (RBC) functionality and deformity as a function of shear stress, whole blood, reported as a maximum elongation index


name: Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis, cell-free DNA, initial (baseline) assessment to determine a patient-specific panel for future comparisons to evaluate for MRD


name: Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis of a patient-specific panel, cell-free DNA, subsequent assessment with comparison to previously analyzed patient specimens to evaluate for MRD


name: Cardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [KIM-1]) with 3 clinical parameters (age, sex, history of cardiac intervention), plasma, algorithm reported as a risk score for obstructive CAD


name: Cardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 [TIMP-1], and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for major adverse cardiac event


name: Pediatrics (vasculitis, Kawasaki disease [KD]), analysis of 3 biomarkers (NT-proBNP, C-reactive protein, and T-uptake), plasma, algorithm reported as a risk score for KD


name: Analysis of 3 biomarkers for Kawasaki disease (NTproBNP, C-reactive protein, and T-uptake) in plasma specimen, algorithm reported as risk score for pediatric Kawasaki disease (KD)


name: Infectious disease (bacterial), quantitative antimicrobial susceptibility reported as phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility for each organism identified


name: Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment


name: Analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products associated with systemic lupus erythematosus by enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence in plasma and whole blood specimens, individual components reported along with algorithmic ystemic lupus erythematosus (SLE)-likelihood assessment


name: Analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products associated with systemic lupus erythematosus by enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence in serum specimen, individual components reported along with algorithmic ystemic lupus erythematosus (SLE)-likelihood assessment


name: Oncology (pancreas), DNA and mRNA next-generation sequencing analysis of 74 genes and analysis of CEA (CEACAM5) gene expression, pancreatic cyst fluid, algorithm reported as a categorical result (ie, negative, low probability of neoplasia or positive, high probability of neoplasia)


name: Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)


name: mRNA gene expression profiling by real-time polymerase chain reaction (RT-PCR) of 35 genes (32 content and 3 housekeeping) associated with malignant melanoma in formalin-fixed paraffin-embedded (FFPE) tissue specimen, algorithm reported as categorical result (ie, benign, intermediate, malignant)


name: Oncology (cutaneous squamous cell carcinoma), mRNA gene expression profiling by RT-PCR of 40 genes (34 content and 6 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical risk result (ie, Class 1, Class 2A, Class 2B)


name: Borrelia burgdorferi (Lyme disease), OspA protein evaluation, urine


name: Oncology (lung cancer), four-probe FISH (3q29, 3p22.1, 10q22.3, 10cen) assay, whole blood, predictive algorithm-generated evaluation reported as decreased or increased risk for lung cancer


name: Pediatrics (congenital epigenetic disorders), whole genome methylation analysis by microarray for 50 or more genes, blood


name: Whole genome methylation analysis by microarray for 50 or more genes associated with congenital epigenetic disorders in blood specimen


name: Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using pretransplant peripheral blood, algorithm reported as a risk score for early acute rejection


name: Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using posttransplant peripheral blood, algorithm reported as a risk score for acute cellular rejection


name: Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique


name: Identification of 20 bacterial and fungal genitourinary pathogens and identification of 16 associated antibiotic-resistance genes by multiplex amplified DNA probe technique


name: Neurology (autism spectrum disorder [ASD]), quantitative measurements of 14 acyl carnitines and microbiome-derived metabolites, liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma, results reported as negative or positive for risk of metabolic subtypes associated with ASD


name: Infectious agent detection by nucleic acid (DNA and RNA), central nervous system pathogen, metagenomic next-generation sequencing, cerebrospinal fluid (CSF), identification of pathogenic bacteria, viruses, parasites, or fungi


name: DNA and mRNA next-generation sequencing analysis in cerebrospinal fluid specimen for detection of organisms causing disease in central nervous system


name: Identification of central nervous system pathogenic bacteria by metagenomic next-generation DNA sequencing in cerebrospinal fluid (CSF) specimen


name: Identification of central nervous system pathogenic fungi by metagenomic next-generation DNA sequencing in cerebrospinal fluid (CSF) specimen


name: Identification of central nervous system pathogenic viruses by metagenomic next-generation DNA sequencing in cerebrospinal fluid (CSF) specimen


name: Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 83 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden


name: Targeted genomic sequence analysis of 83 or more genes in cell free circulating DNA for detection of abnormalities associated with solid organ cancers


name: Fetal aneuploidy (trisomy 13, 18, and 21), DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy, includes sex reporting, if performed


name: DNA sequence analysis of selected regions for detection of abnormal fetal chromosome number (trisomy 13, 18, and 21) in maternal plasma specimen, algorithm reported as risk score for each trisomy, includes sex reporting, if performed


name: DNA sequence analysis of selected regions for fetal aneuploidy (trisomy 13, 18, and 21) in maternal plasma specimen, algorithm reported as risk score for each trisomy


name: Drug assay, definitive, 120 or more drugs and metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS), includes specimen validity and algorithmic analysis describing drug or metabolite and presence or absence of risks for a significant patient-adverse event, per date of service


name: Definitive drug testing for 120 or more drugs and metabolites in urine specimen


name: Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden utilizing DNA and RNA from tumor with DNA from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations


name: Exome and transcriptome sequence analysis of DNA and RNA from tumor with DNA from normal blood or saliva for subtraction, report of clinically significant mutations with therapy associations


name: Exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden in DNA and RNA from tumor specimen with DNA from normal blood specimen for subtraction, with report of clinically significant mutations with therapy associations


name: Exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden in DNA and RNA from tumor specimen with DNA from normal saliva specimen for subtraction, with report of clinically significant mutations with therapy associations


name: Infectious agent detection by nucleic acid (DNA or RNA), vaginal pathogen panel, identification of 27 organisms, amplified probe technique, vaginal swab


name: Vaginal pathogen panel for identification of 27 organisms by amplified DNA probe technique in vaginal swab specimen


name: Oncology (hematolymphoid neoplasia), optical genome mapping for copy number alterations and gene rearrangements utilizing DNA from blood or bone marrow, report of clinically significant alterations


name: Optical genome mapping of DNA from blood or bone marrow specimen, report of clinically significant alterations associated with blood or lymph system cancers


name: Optical genome mapping for copy number alterations and gene rearrangements associated with hematolymphoid neoplasia utilizing DNA from blood specimen, with report of clinically significant alterations


name: Optical genome mapping for copy number alterations and gene rearrangements associated with hematolymphoid neoplasia utilizing DNA from bone marrow specimen, with report of clinically significant alterations


name: Oncology (pan-tumor), genetic profiling of 8 DNA-regulatory (epigenetic) markers by quantitative polymerase chain reaction (qPCR), whole blood, reported as a high or low probability of responding to immune checkpoint-inhibitor therapy


name: Genetic profiling of 8 epigenetic markers to evaluate probability of responding to immune checkpoint-inhibitor therapy for cancer


name: Oncology (liver), surveillance for hepatocellular carcinoma (HCC) in high-risk patients, analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement of serum of AFP/AFP-L3 and oncoprotein des-gamma-carboxy-prothrombin (DCP), algorithm reported as normal or abnormal result


name: Survelliance for liver cancer in high risk patients using algorithm


name: Oncology (solid organ), targeted genomic sequence analysis, formalin-fixed paraffin-embedded (FFPE) tumor tissue, DNA analysis, 84 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden


name: Targeted genomic sequence analysis of 84 or more genes for detection of abnormalities associated with cancer of body organ


name: Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, fetal sample, identification and categorization of genetic variants


name: Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent)


name: Whole genome sequence analysis of comparator genome (parent) for detection of abnormalities associated with rare constitutional/heritable diseases


name: Whole genome sequence analysis for detection of small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions in blood specimen, with identification and categorization of genetic variants associated with rare constitutional and heritable disorders, each comparator genome


name: Whole genome sequence analysis for detection of small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions in blood specimen, with identification and categorization of genetic variants associated with rare constitutional and heritable disorders, each parent genome


name: Whole genome sequence analysis for detection of small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions in saliva specimen, with identification and categorization of genetic variants associated with rare constitutional and heritable disorders, each comparator genome


name: Whole genome sequence analysis for detection of small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions in saliva specimen, with identification and categorization of genetic variants associated with rare constitutional and heritable disorders, each parent genome


name: Oncology (plasma cell disorders and myeloma), circulating plasma cell immunologic selection, identification, morphological characterization, and enumeration of plasma cells based on differential CD138, CD38, CD19, and CD45 protein biomarker expression, peripheral blood


name: Evaluation of plasma cells for detection of abnormalities associated with plasma cell disorders and myeloma


name: Oncology (solid tumor), circulating tumor cell selection, identification, morphological characterization, detection and enumeration based on differential EpCAM, cytokeratins 8, 18, and 19, and CD45 protein biomarkers, and quantification of HER2 protein biomarker-expressing cells, peripheral blood


name: Evaluation of circulating solid tumor cells in peripheral blood


name: Oncology (prostate), mRNA expression profiling of HOXC6 and DLX1, reverse transcription polymerase chain reaction (RT-PCR), first-void urine following digital rectal examination, algorithm reported as probability of high-grade cancer


name: mRNA expression profiling of genes associated with high-grade prostate cancer


name: Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient's tumor and germline DNA, reported as absence or presence of MRD, with disease-burden correlation, if appropriate


name: DNA assays for detection of minimal residual disease in cancer


name: Analysis of minimal residual disease (MRD) from plasma specimen, with assays personalized to patient based on prior next-generation sequencing of patient's tumor and germline DNA, reported as absence or presence of MRD in pan-cancer


name: Fetal aneuploidy DNA sequencing comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploid


name: Fetal DNA sequencing of products of conception for detection of abnormal chromosome number


name: Oncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B, osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent immunoassay (ECLIA) for CA19-9, serum, diagnostic algorithm reported qualitatively as positive, negative, or borderline


name: Multiplex immunoassay for markers of pancreatic cancer in serum


name: Oncology (prostate), exosome-based analysis of 442 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as molecular evidence of no-, low-, intermediate- or high-risk of prostate cancer


name: Exosome-based analysis of 442 small noncoding RNAs in urine to evaluate risk of prostate cancer


name: Hepatology (nonalcoholic fatty liver disease [NAFLD]), semiquantitative evaluation of 28 lipid markers by liquid chromatography with tandem mass spectrometry (LC-MS/MS), serum, reported as at-risk for nonalcoholic steatohepatitis (NASH) or not NASH


name: Evaluation of 28 lipid markers for risk of nonalcoholic fatty liver disease


name: Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 (0345U)


name: Genomic analysis panel of 15 genes for detection of abnormalities assocated with mental health disorders


name: Genomic analysis panel with variant analysis of 15 genes, including deletion and duplication analysis of cytochrome P450 2D6 (CYP2D6)


name: Beta amyloid, Aβ40 and Aβ42 by liquid chromatography with tandem mass spectrometry (LC-MS/MS), ratio, plasma


name: Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 16 gene report, with variant analysis and reported phenotypes


name: DNA analysis of 16 genes involved in drug metabolism or processing


name: DNA analysis of 16 genes associated with drug metabolism in buccal specimen, with variant analysis and reported phenotypes


name: DNA analysis of 16 genes associated with drug metabolism in whole blood specimen, with variant analysis and reported phenotypes


name: Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 25 gene report, with variant analysis and reported phenotypes


name: DNA analysis of 25 genes involved in drug metabolism or processing


name: DNA analysis of 25 genes associated with drug metabolism in buccal specimen, with variant analysis and reported phenotypes


name: DNA analysis of 25 genes associated with drug metabolism in whole blood specimen, with variant analysis and reported phenotypes


name: Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis, including reported phenotypes and impacted gene-drug interactions


name: DNA analysis of 27 genes involved in drug metabolism or processing, report including gene-drug interactions


name: DNA analysis of 27 genes associated with drug metabolism in buccal specimen, with variant analysis, including reported phenotypes and impacted gene-drug interactions


name: DNA analysis of 27 genes associated with drug metabolism in whole blood specimen, with variant analysis, including reported phenotypes and impacted gene-drug interactions


name: Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis and reported phenotypes


name: DNA analysis of 27 genes involved in drug metabolism or processing, analysis and reported phenotypes


name: DNA analysis of 27 genes associated with drug metabolism in buccal specimen, with variant analysis and reported phenotypes


name: DNA analysis of 27 genes associated with drug metabolism in whole blood specimen, with variant analysis and reported phenotypes


name: Infectious disease (bacterial or viral), biochemical assays, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP-10), and C-reactive protein, serum, algorithm reported as likelihood of bacterial infection


name: Biochemical assays for markers of bacterial infection


name: Biochemical assays for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP-10), and C-reactive protein in serum, algorithm reported as likelihood of bacterial infection


name: Infectious disease (bacterial vaginosis and vaginitis), multiplex amplified probe technique, for detection of bacterial vaginosis-associated bacteria (BVAB-2, Atopobium vaginae, and Megasphera type 1), algorithm reported as detected or not detected and separate detection of Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata/Candida krusei, and trichomonas vaginalis, vaginal-fluid specimen, each result reported as detected or not detected


name: Detection of bacteria causing vaginosis and vaginitis by multiplex amplified nucleic acid probe technique


name: Infectious agent detection by nucleic acid (DNA), Chlamydia trachomatis and Neisseria gonorrhoeae, multiplex amplified probe technique, urine, vaginal, pharyngeal, or rectal, each pathogen reported as detected or not detected


name: Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by multiplex amplified DNA probe technique


name: Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in pharyngeal specimen by multiplex amplified DNA probe technique


name: Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in rectal specimen by multiplex amplified DNA probe technique


name: Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimen by multiplex amplified DNA probe technique


name: Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in vaginal specimen by multiplex amplified DNA probe technique


name: Human papilloma virus (HPV), high-risk types (ie, 16, 18, 31, 33, 45, 52 and 58) qualitative mRNA expression of E6/E7 by quantitative polymerase chain reaction (qPCR)


name: Human papilloma virus (HPV) by quantitative polymerase chain reaction (qPCR)


name: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use


name: Dengue vaccine, quadrivalent, live, 2 dose schedule, for subcutaneous use


name: Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use


name: Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use


name: Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for percutaneous use


name: Hepatitis B (HepB) vaccine, CpG-adjuvanted, adult dosage, 2 dose schedule, for intramuscular use


name: Hepatitis B (HepB) vaccine, CpG-adjuvanted, adult dosage, 4 dose schedule, for intramuscular use


name: Eye training exercise performed by health care professional


name: Orthoptic training by qualified health care professional


name: Bilateral imaging of retina for detection of disease with point-of-care autonomous analysis and report


name: Bilateral imaging of retina for monitoring of disease with point-of-care autonomous analysis and report


name: Unilateral imaging of retina for detection of disease with point-of-care autonomous analysis and report


name: Unilateral imaging of retina for monitoring of disease with point-of-care autonomous analysis and report


name: Evaluation of eye adaptation to light and dark with interpretation and report


name: Injection for nonselective imaging of pulmonary artery during heart catheterization


name: Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective pulmonary arterial angiography, unilateral (List separately in addition to code for primary procedure)


name: Injection for selective imaging of pulmonary artery during heart catheterization, on one side of body


name: Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective pulmonary arterial angiography, bilateral (List separately in addition to code for primary procedure)


name: Injection for selective imaging of pulmonary artery during heart catheterization, on both sides of body


name: Bilateral injection procedure for selective pulmonary venous angiography of each distinct pulmonary vein with imaging supervision, interpretation, and report, during cardiac catheterization


name: Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective pulmonary venous angiography of each distinct pulmonary vein during cardiac catheterization (List separately in addition to code for primary procedure)


name: Injection for selective imaging of pulmonary vein during heart catheterization


name: Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective pulmonary angiography of major aortopulmonary collateral arteries (MAPCAs) arising off the aorta or its systemic branches, during cardiac catheterization for congenital heart defects, each distinct vessel (List separately in addition to code for primary procedure)


name: Injection for selective imaging of major aortopulmonary collateral arteries during heart catheterization


name: Injection procedure for selective pulmonary angiography of major aortopulmonary collateral arteries (MAPCAs) arising off systemic branches of aorta imaging supervision, interpretation, and report, during cardiac catheterization for congenital heart defects, each distinct vessel


name: Injection procedure for selective pulmonary angiography of major aortopulmonary collateral arteries (MAPCAs) arising off the aorta with imaging supervision, interpretation, and report, during cardiac catheterization for congenital heart defects, each distinct vessel


name: Quantitative pupillometry with physician or other qualified health care professional interpretation and report, unilateral or bilateral


name: Measurement of pupil with healthcare professional interpretation and report


name: Bilateral quantitative pupillometry with interpretation and report by a qualified health professional


name: Bilateral quantitative pupillometry with interpretation and report by physician


name: Unilateral quantitative pupillometry with interpretation and report by a qualified health professional


name: Unilateral quantitative pupillometry with interpretation and report by physician


name: Multiple-family group behavior management/modification training for parent(s)/guardian(s)/caregiver(s) of patients with a mental or physical health diagnosis, administered by physician or other qualified health care professional (without the patient present), face-to-face with multiple sets of parent(s)/guardian(s)/caregiver(s)


name: Multiple-family group behavior management/modification training for parent(s)/guardian(s)/caregiver(s) of patients with a mental or physical health diagnosis, administered by physician or other qualified health care professional (without the patient present), face-to-face with multiple sets of parent(s)/guardian(s)/caregiver(s); initial 60 minutes


name: Multiple-family group behavior management/modification training, face-to-face, initial 60 minutes


name: Face-to face multiple-family group behavior management/modification training for parents/guardians/caregivers of patients with mental health diagnosis, administered by a qualified health care professional, initial 60 minutes


name: Face-to face multiple-family group behavior management/modification training for parents/guardians/caregivers of patients with mental health diagnosis, administered by physician, initial 60 minutes


name: Face-to face multiple-family group behavior management/modification training for parents/guardians/caregivers of patients with physical health diagnosis, administered by a qualified health care professional, initial 60 minutes


name: Face-to face multiple-family group behavior management/modification training for parents/guardians/caregivers of patients with physical health diagnosis, administered by physician or other qualified health care professional, initial 60 minutes


name: Multiple-family group behavior management/modification training for parent(s)/guardian(s)/caregiver(s) of patients with a mental or physical health diagnosis, administered by physician or other qualified health care professional (without the patient present), face-to-face with multiple sets of parent(s)/guardian(s)/caregiver(s); each additional 15 minutes (List separately in addition to code for primary service)


name: Multiple-family group behavior management/modification training, face-to-face, each additional 15 minutes


name: Face-to face multiple-family group behavior management/modification training for parents/guardians/caregivers of patients with mental health diagnosis, administered by a qualified health care professional, each additional 15 minutes


name: Face-to face multiple-family group behavior management/modification training for parents/guardians/caregivers of patients with mental health diagnosis, administered by physician, each additional 15 minutes


name: Face-to face multiple-family group behavior management/modification training for parents/guardians/caregivers of patients with physical health diagnosis, administered by a qualified health care professional, each additional 15 minutes


name: Face-to face multiple-family group behavior management/modification training for parents/guardians/caregivers of patients with physical health diagnosis, administered by physician or other qualified health care professional, each additional 15 minutes


name: Remote therapeutic monitoring (eg, therapy adherence, therapy response)


name: Device supply with daily recording and programmed alert transmission for remote therapeutic monitoring of respiratory system, each 30 days


name: Device supply with daily recording and programmed alert transmission for remote therapy adherence monitoring of respiratory system, each 30 days


name: Device supply with daily recording for remote therapeutic monitoring of respiratory system, each 30 days


name: Device supply with daily recording for remote therapy adherence monitoring of respiratory system, each 30 days


name: Device supply with programmed alert transmission for remote therapeutic monitoring of respiratory system, each 30 days


name: Device supply with programmed alert transmission for remote therapy adherence monitoring of respiratory system, each 30 days


name: Device supply with programmed alert transmission for remote therapy response monitoring of respiratory system, each 30 days


name: Device supply with scheduled recording and programmed alert transmission for remote therapy response monitoring of respiratory system, each 30 days


name: Device supply with scheduled recording for remote therapeutic monitoring of respiratory system, each 30 days


name: Device supply with scheduled recording for remote therapy adherence monitoring of respiratory system, each 30 days


name: Device supply with scheduled recording and transmission for remote monitoring of musculoskeletal system, per 30 days


name: Device supply with programmed alert transmission for remote therapeutic monitoring of musculoskeletal system, each 30 days


name: Device supply with programmed alert transmission for remote therapy adherence monitoring of musculoskeletal system, each 30 days


name: Device supply with scheduled recording and programmed alert transmission for remote therapeutic monitoring of musculoskeletal system, each 30 days


name: Device supply with scheduled recording and programmed alert transmission for remote therapy adherence monitoring of musculoskeletal system, each 30 days


name: Device supply with scheduled recording and programmed alert transmission for remote therapy response monitoring of rmusculoskeletal system, each 30 days


name: Device supply with scheduled recording for remote therapeutic monitoring of musculoskeletal system, each 30 days


name: Device supply with scheduled recording for remote therapy adherence monitoring of musculoskeletal system, each 30 days


name: Remote therapeutic monitoring (eg, therapy adherence, therapy response); device(s) supply with scheduled (eg, daily) recording(s) and/or programmed alert(s) transmission to monitor cognitive behavioral therapy, each 30 days


name: Device supply with scheduled recording and transmission for remote monitoring of cognitive behavioral therapy, per 30 days


name: Device supply with daily recording and programmed alert transmission for remote therapeutic monitoring of cognitive behavior therapy, each 30 days


name: Device supply with daily recording and programmed alert transmission for remote therapy adherence monitoring of cognitive behavior therapy, each 30 days


name: Device supply with daily recording for remote therapeutic monitoring of cognitive behavior therapy, each 30 days


name: Device supply with daily recording for remote therapy adherence monitoring of cognitive behavior therapy, each 30 days


name: Device supply with programmed alert transmission for remote therapeutic monitoring of cognitive behavior therapy, each 30 days


name: Device supply with programmed alert transmission for remote therapy adherence monitoring of cognitive behavior therapy, each 30 days


name: Device supply with programmed alert transmission for remote therapy response monitoring of cognitive behavior therapy, each 30 days


name: Device supply with scheduled recording and programmed alert transmission for remote therapeutic monitoring of cognitive behavior therapy, each 30 days


name: Device supply with scheduled recording and programmed alert transmission for remote therapy adherence monitoring of cognitive behavior therapy, each 30 days


name: Device supply with scheduled recording and programmed alert transmission for remote therapy response monitoring of cognitive behavior therapy, each 30 days


name: Device supply with scheduled recording for remote therapeutic monitoring of cognitive behavior therapy, each 30 days


name: Device supply with scheduled recording for remote therapy adherence monitoring of cognitive behavior therapy, each 30 days


name: Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance


name: Shockwave destruction of calcified plaque in coronary artery accessed through skin using catheter


name: Cardiac acoustic waveform recording with automated analysis and generation of coronary artery disease risk score


name: Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear


name: Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; adipose tissue harvesting, isolation and preparation of harvested cells, including incubation with cell dissociation enzymes, filtration, washing, and concentration of ADRCs


name: Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; injection into supraspinatus tendon including ultrasound guidance, unilateral


name: Posterior vertebral joint replacement, including bilateral facetectomy, laminectomy, and radical discectomy, including imaging guidance, lumbar spine, single segment


name: Replacement of posterior joint in single segment of spine in lower back (lumbar) using imaging guidance


name: Percutaneous electrical nerve field stimulation, cranial nerves, without implantation


name: Electrical nerve field stimulation of cranial nerves through skin


name: Quantitative computed tomography (CT) tissue characterization, including interpretation and report, obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging


name: Quantitative computed tomography (CT scan) tissue characterization with interpretation and report


name: Quantitative computed tomography (CT) tissue characterization, including interpretation and report, obtained with concurrent CT examination of any structure contained in the concurrently acquired diagnostic imaging dataset (List separately in addition to code for primary procedure)


name: Quantitative magnetic resonance cholangiopancreatography (QMRCP), including data preparation and transmission, interpretation and report, obtained without diagnostic magnetic resonance imaging (MRI) examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session


name: Quantitative magnetic resonance (MR scan) imaging of gallbladder, bile ducts, pancreas and pancreatic duct cholangiopancreatography (QMRCP), with data preparation and transmission, interpretation and report


name: Quantitative magnetic resonance cholangiopancreatography (QMRCP), including data preparation and transmission, interpretation and report, obtained with diagnostic magnetic resonance imaging (MRI) examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code for primary procedure)


name: Quantitative magnetic resonance (MR scan) imaging of gallbladder, bile ducts, pancreas and pancreatic duct cholangiopancreatography (QMRCP), with data preparation and transmission, interpretation and report and with diagnostic magnetic resonance imaging (MRI) examination of same anatomy


name: Implantation of vestibular nerve stimulation device in one ear


name: Removal of vestibular nerve stimulation device from one ear


name: Removal and replacement of vestibular nerve stimulation device from one ear


name: Diagnostic analysis of vestibular implant, unilateral


name: Diagnostic analysis of vestibular implant, unilateral; with initial programming


name: Diagnostic analysis and initial programming of vestibular nerve stimulation device in one ear


name: Diagnostic analysis of vestibular implant, unilateral; with subsequent programming


name: Trabeculotomy by laser, including optical coherence tomography (OCT) guidance


name: Laser incision of drainage tissue within eye (trabeculotomy) using optical coherence tomography (OCT) guidance


name: Augmentative AI-based facial phenotype analysis with report


name: Augmentative artificial intelligence-based analysis of facial features (facial phenotype) for possible genetic syndromes with report


name: Remote real-time, motion capture-based neurorehabilitative therapy ordered by a physician or other qualified health care professional


name: Remote real-time, motion capture-based neurorehabilitative therapy ordered by a physician or other qualified health care professional; supply and technical support, per 30 days


name: Device supply and technical support for remote real-time, motion capture-based neurorehabilitative therapy, per 30 days


name: Remote real-time, motion capture-based neurorehabilitative therapy ordered by a physician or other qualified health care professional; treatment management services by a physician or other qualified health care professional, per calendar month


name: Treatment management service for remote real-time, motion capture-based neurorehabilitative therapy, per calendar month


name: Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with primary craniotomy (List separately in addition to code for primary procedure)


name: Colonic lavage, 35 or more liters of water, gravity-fed, with induced defecation, including insertion of rectal catheter


name: Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination


name: Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation


name: Destruction of prostate cancer by magnetic field induction


name: Remote autonomous algorithm-based recommendation system for insulin dose calculation and titration


name: Remote autonomous algorithm-based recommendation system for insulin dose calculation and titration; initial set-up and patient education


name: Remote autonomous algorithm-based recommendation system for insulin dose calculation and titration; provision of software, data collection, transmission, and storage, each 30 days


name: Absolute quantitation of myocardial blood flow (AQMBF), single-photon emission computed tomography (SPECT), with exercise or pharmacologic stress, and at rest, when performed (List separately in addition to code for primary procedure)


name: SPECT measurement of blood flow to heart muscle


name: Bone strength and fracture risk using finite element analysis of functional data and bone mineral density (BMD), with concurrent vertebral fracture assessment, utilizing data from a computed tomography scan, retrieval and transmission of the scan data, measurement of bone strength and BMD and classification of any vertebral fractures, with overall fracture-risk assessment, interpretation and report


name: Bone strength and fracture-risk assessment with assessment for broken spine bones


name: Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X-ray data, assessment of bone strength and fracture risk and BMD, interpretation and report


name: Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD)


name: Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X-ray data, assessment of bone strength and fracture risk and BMD, interpretation and report; with single-view digital X-ray examination of the hand taken for the purpose of DXR-BMD


name: Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD) with single-view digital X-ray of hand


name: Insertion of bioprosthetic valve, open, femoral vein, including duplex ultrasound imaging guidance, when performed, including autogenous or nonautogenous patch graft (eg, polyester, ePTFE, bovine pericardium), when performed


name: Insertion of bioprosthetic valve in vein of thigh (femoral vein)


name: Cardiac focal ablation utilizing radiation therapy for arrhythmia


name: Cardiac focal ablation utilizing radiation therapy for arrhythmia; noninvasive arrhythmia localization and mapping of arrhythmia site (nidus), derived from anatomical image data (eg, CT, MRI, or myocardial perfusion scan) and electrical data (eg, 12-lead ECG data), and identification of areas of avoidance


name: Noninvasive localization and mapping of heart tissue causing abnormal heart rhythm for radiation treatment for focal destruction of arrhythmia site


name: Cardiac focal ablation utilizing radiation therapy for arrhythmia; conversion of arrhythmia localization and mapping of arrhythmia site (nidus) into a multidimensional radiation treatment plan


name: Cardiac focal ablation utilizing radiation therapy for arrhythmia; delivery of radiation therapy, arrhythmia


name: Injections of stem cell product into perianal perifistular soft tissue, including fistula preparation (eg, removal of setons, fistula curettage, closure of internal openings)


name: Injections of stem cell product into soft tissue around abnormal drainage tract next to anus


name: Digital Pathology Digitization Procedures


name: Digitization of glass microscope slides for level II, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for level II surgical pathology


name: Digitization of glass microscope slides for level III, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for level III surgical pathology


name: Digitization of glass microscope slides for level IV, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for level IV surgical pathology


name: Digitization of glass microscope slides for level V, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for level V surgical pathology


name: Digitization of glass microscope slides for level VI, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for level VI surgical pathology


name: Digitization of glass microscope slides for special stain, including interpretation and report, group I, for microorganisms (eg, acid fast, methenamine silver) (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for Group I special stain for microorganisms


name: Digitization of glass microscope slides for special stain, including interpretation and report, group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for Group II special stain


name: Digitization of glass microscope slides for special stain, including interpretation and report, histochemical stain on frozen tissue block (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for special stain, including interpretation and report, group III, for enzyme constituents (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for Group III special stain


name: Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, initial single antibody stain procedure (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, initial single antibody stain procedure


name: Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each additional single antibody stain procedure (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, each additional single antibody stain procedure


name: Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each multiplex antibody stain procedure (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, each multiplex antibody stain procedure


name: Digitization of glass microscope slides for morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen, each single antibody stain procedure, manual (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for morphometric analysis, tumor immunohistochemistry, each manual single antibody stain procedure


name: Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy)


name: Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to concurrently performed electrocardiogram (List separately in addition to code for primary procedure)


name: Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to previously performed electrocardiogram


name: Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; first nerve


name: Transcutaneous magnetic stimulation of peripheral nerve by focused low-frequency electromagnetic pulse, initial treatment on first nerve


name: Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; each additional nerve (List separately in addition to code for primary procedure)


name: Transcutaneous magnetic stimulation of peripheral nerve by focused low-frequency electromagnetic pulse, initial treatment on additional nerve


name: transcutaneous magnetic stimulation of peripheral nerve by focused low-frequency electromagnetic pulse, subsequent treatment, first nerve


name: Virtual reality technology to assist therapy (List separately in addition to code for primary procedure)


name: Virtual Reality Patient Procedural Dissociation


name: Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status


name: Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older


name: Virtual reality (VR) procedural dissociation services provided by same health care professional performing diagnostic or therapeutic procedure VR procedural dissociation supports, initial 15 minutes, patient age 5 years or older


name: Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; each additional 15 minutes intraservice time (List separately in addition to code for primary service)


name: Virtual reality (VR) procedural dissociation services provided by same health care professional performing diagnostic or therapeutic procedure VR procedural dissociation supports, additional 15 minutes


name: Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports


name: Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; initial 15 minutes of intraservice time, patient age 5 years or older


name: Virtual reality (VR) procedural dissociation services provided by different health care professional than health care professional performing diagnostic or therapeutic procedure VR procedural dissociation supports, initial 15 minutes, patient age 5 years or older